Barbara Trautner, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Genentech
    Topic:
    tocilizumab for COVID pneumonia
    Date added:
    Date updated:
    05/03/2024
  • Attribution:
    Self
    Type of financial relationship:
    Research Funding (if you were the principal or named investigator)
    Ineligible company:
    Genentech
    Topic:
    EMPACTA trial (tocilizumab for COVID pneumonia)
    Date added:
    Date updated:
    05/03/2024
  • Attribution:
    Self
    Type of financial relationship:
    Research Funding (if you were the principal or named investigator)
    Ineligible company:
    Peptilogics
    Topic:
    prosthetic joint infection
    Date added:
    07/03/2023
    Date updated:
    05/03/2024
Return to 2024 Infectious Disease Board Review Course